Identifying therapeutic targets for cancer: 2,094 circulating proteins and risk of nine cancers

Abstract

AbstractBackgroundUnderstanding the role of circulating proteins in cancer risk can reveal key biological pathways and identify novel therapeutic targets for cancer prevention.MethodsWe investigated the associations of 2,094 circulating proteins with risk of nine common cancers (bladder, breast, endometrium, head and neck, lung, ovary, pancreas, kidney, and malignant non-melanoma) usingcispQTL Mendelian randomisation (MR) and colocalization. Findings for proteins with support from both MR, after correction for multiple-testing, and colocalization were replicated using an independent cancer GWAS. Additionally, MR and colocalization phenome-wide association analyses (PHEWAS) were conducted to identify potential adverse side-effects of altering risk proteins. Finally, we mapped cancer risk proteins to drug and ongoing clinical trials targets.ResultsWe identified 40 proteins associated with cancer risk, of which a majority replicated and were novel. Among these were proteins associated with common cancers, such as PLAUR and risk of breast cancer [odds ratio per standard deviation increment (OR): 2.27, 95% CI: 1.88 to 2.74], and with high-mortality cancers, such as CTRB1 and pancreatic cancer [OR: 0.79, 95% CI: 0.73 to 0.85]. PHEWAS highlighted multiple links between proteins and potential adverse effects of protein-altering interventions. Additionally, 18 proteins associated with cancer risk mapped to existing therapeutic interventions, while 15 were not currently known to be under clinical investigation, such as GAS1 and triple negative breast cancer [OR: 1.88, 95% CI: 1.42 to 2.47].ConclusionOur findings emphasize the importance of proteomics for improving our understanding of cancer aetiology. Additionally, we demonstrate the benefit of in-depth protein PHEWAS analyses on risk proteins to identify potential adverse side-effects of protein-altering interventions. Using these methods, we identify a subset of risk proteins as potential drug targets for the prevention and treatment of cancer as well as opportunities for drug repurposing.